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increases the number of chondrocyte population doublings in
vitro.
Conclusions: Taken together these observations indicate that
both aging and excessive articular surface contact stress may
cause oxidative damage to chondrocytes, and that strategies that
involve treating age related osteoarthritis in its earliest stages
and joint injuries may be beneﬁcial if they minimize deleterious
mechanical stresses and prevent propagation of chondrocyte
oxidative damage.
BIOMECHANICS AND MECHANOBIOLOGY OF
OSTEOARTHRITIS: THE YEAR IN REVIEW
F. Guilak
Duke University Medical Center, Durham, NC
Purpose: Biomechanical factors play a critical role in the onset
and progression of osteoarthritis, yet the mechanisms by which
biomechanical and molecular factors interact to control cartilage
physiology and pathology are not fully understood. Here we will
review recent studies focusing on osteoarthritis and cartilage that
have provided new insights on the role of biomechanics in OA.
Methods: In the past year, a number of exciting new studies
have revealed new details on the role of biomechanical factors in
the development, growth, remodeling, degeneration, and regen-
eration of joint tissues. Recent studies have focused at a variety
of different scales and topics, including:
• Micro- and nano-mechanics of extracellular matrix molecules
• Cartilage cell and tissue mechanical properties
• Mechanobiology of cartilage and other joint tissues
• Interactions of biomechanics and inﬂammation in obesity
• The role of biomechanics in tissue engineering and cartilage
regeneration
Results: These studies provide further evidence of the important
role that biomechanical factors play in the function of the synovial
joint, and in particular, how mechanical factors inﬂuence cell
biology and vice versa.
Conclusions: An improved understanding of these mechanisms
will hopefully lead to improved physical and pharmacologic ther-
apies for osteoarthritis.
CLINICAL AND MOLECULAR GENETICS – THE YEAR IN
REVIEW
J. Loughlin
University of Oxford, Oxford, United Kingdom
Purpose: The past year has been another highly productive one
in the ﬁeld of clinical and molecular genetics. New loci have
been reported, and older loci have either been replicated or
despatched from any further interest, in the objective style that
makes genetic linkage and association analysis such powerful
tools.
One of the most exciting new genes is GDF5, which codes for
growth and differentiation factor 5 (also known as cartilage-
derived morphogenetic protein 1). This signalling molecule,
which is a member of the TGF-β superfamily, is active during
joint formation and in mature tissues, implying both a design
and maintain function. A common polymorphism in a regulatory
element of the gene demonstrated a highly compelling associa-
tion in Asian populations and this was soon replicated in large
European cohorts. Subsequent meta-analysis on over 10,000
individuals has conﬁrmed the global relevance of this gene to OA
susceptibility whilst in-vitro and in-vivo functional studies have re-
vealed that the associated polymorphism reduces the expression
of GDF5 in chondrocytes. GDF5 joins the growing band of sig-
nalling or signalling-related genes that harbour polymorphisms
that confer susceptibility for OA. This is an exciting development
as these pathways are amenable to intervention.
Running alongside the new discoveries are the rumblings of
the agnostic genome-wide association scans. There are highly
progressed plans afoot for scans in North America, Europe and
Asia on large case-control cohorts. Very soon the OA research
community will be in the enviable position of understanding the
molecular genetic architecture of OA with quite high precision.
These are exciting times indeed.
CARTILAGE EXTRACELLULAR MATRIX IN HEALTH AND
DISEASE
D. Heinegård
Lund University, Lund, Sweden
The cartilage extracellular matrix is progressively broken down
and destroyed in joint disease leading to loss of tissue and
joint function. There is accumulating evidence for degradation of
cartilage extracellular matrix molecules at speciﬁc sites, following
the original observations of one unique speciﬁc cleavage site by
collagenases of triple helical collagen II and a total of ﬁve unique
sites in aggrecan by aggrecanases. In these cases the normal
and pathological turnover is accomplished by the same enzymes
and the same sites are cleaved. New information on degradation
of other matrix constituents indicates that there are processes
involving enzymes that appear more unique to a pathological
process and leading to unique cleavage sites. Antibodies raised
to the new terminals produced in the substrate proteins offer
opportunities to development of assays with a much higher
speciﬁcity for the pathological process. Such assays can be
used to depict sequence of events in the destruction process.
To understand the repair process that invariably is associated
with breakdown, information needs to be gained about assembly
of the constituent building blocks into larger structural assemblies
such as the collagen ﬁbrillar networks. There is accumulating
information on the role of various cartilage matrix constituents
in the regulation of the assembly of e.g. the collagen network.
Such molecules include speciﬁc subsets of chondroitin sulfate,
COMP and the leucine rich proteins, where there are examples
of both accelerators and inhibitors. Dysregulation of any of these
constituents is likely to hamper the process of tissue repair.
A key element is how cells react to events of the matrix. This
is partly governed by mechanical load and by alterations in
matrix constituents able to bind to receptors at the cell surface.
New information is becoming available on interactions with a
variety of cell surface receptors including integrins, cell surface
proteoglycans and a number of others for speciﬁc molecules.
Such interactions will be involved in modulating cellular activities
relevant to the integrity of the matrix.
Degradation of matrix constituent will produce fragments of vari-
ous macromolecules. Some of the fragment will be able to bind
to and affect other players such as systems of factors and cells.
One classical example is the ﬁbronectin fragments that activate
e.g. catabolic and inﬂammatory responses. It is now becoming
apparent that also degradation of collagen will yield similarly ac-
tive fragments. Inﬂammation is an almost invariable component
of all joint diseases. New data are indicating that components
in the cartilage may bind and regulate various players in the in-
ﬂammatory system including macrophages and the complement
system. This may yield activation of inﬂammation that in turn
effect the cartilage to further breakdown in a vicious circle.
ADVANCES IN CLINICAL TRIAL DESIGN FOR
OSTEOARTHRITIS
R.D. Altman
UCLA, Agua Dulce, CA
Instruments that measure change in osteoarthritis (OA) are not
as sensitive as desired. In addition, the placebo response con-
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tinues to restrict the effect size of the studied drug or device
and a trial of any length of time will allow escape therapy. There
is debate as to the ability to generalize trials that use the ﬂare
design as a way to select patients more likely to have a symptom
response to therapy. Indeed, patient selection continues to be a
major drawback in many trials.
Oral agent for symptomatic therapy: Clinical trials have ex-
panded the number of subjects studied in order to capture less
common adverse events. Nonsteroidal antiinﬂammatory drug
(NSAID) trials have expanded to try to capture beneﬁt (eg gas-
trointestinal with Coxibs) and to clarify risk (eg cardiovascular).
Measures of improvement continue to use pain as an outcome.
The Western Ontario McMaster Universities (WOMAC) subscale
for pain has commonly replaced the single visual analog scale
(VAS) for pain in clinical trials. However, new instruments are be-
ing developed (eg KOOS, HOOS, OMERACT/OARSI Pain scale).
Although as efﬁcient as the WOMAC, the Lequesne algofunc-
tional index, is not able to separate the pain component and is
not as frequently in use. OMERACT has recommended that all
clinical OA trials should include a measure of pain, function and
a patient global with a radiograph for safety in trials of a year
of more. Some regulatory agencies have required the former 3
items to be signiﬁcant as primary measures, expanding the size
of the trials. Since symptoms in OA are often variable, clinical
trials often require persistence of pain. The length of trials for
symptoms is generally accepted to be of over 3 months for
durability of response and a year for safety.
Topical agent for symptomatic therapy: Although in use many
years, there are few recent clinical trials that demonstrate beneﬁt.
Trials of topical therapy suffers from a high placebo response,
higher that oral therapy, compromising the effect size. Topical
therapy only affects the treated joint_pain from other sites, par-
ticularly contralateral joint, other joints, spine, effects the percep-
tion of pain from the signal joint. The application of the placebo
probably also increases the placebo response. The ﬂare design
seems to be needed for separation from control. Intraarticular
agents for symptomatic therapy
There has been considerable difﬁculty in consistently demon-
strating an effect size of an Intraarticular agent over a control
group. The controls often receive an injection which increases
the placebo response, in addition to the potential beneﬁt of In-
traarticular saline or local lidocaine. In addition, pain from other
sites effect the perceived pain from the signal joint. The hip joint
has required ﬂuoroscopy or ultrasound to guide injections.
Structure (disease) modifying agents: No agent has been uni-
formly accepted as structure modifying. Although modiﬁed x-ray
techniques have improved the ability to detect change in joint
structure, the sensitivity remains less than ideal. Magnetic res-
onance imaging has been standardized and is more sensitive
to change. MRI can not only quantitate cartilage volume, but is
able to measure other joint structures. Study length is at least
2 years. Some measure of symptom response is measured in
clinical trials. Time to the indication of total joint replacement
is under development; at present, time to joint replacement is
a secondary outcome variable. Additional secondary measures
include markers of disease progression.
There have been many modiﬁcations of clinical trials in the last
few years. Reﬁnement in study design continues.
